In a Phase 1b clinical trial with patients with advanced melanoma, anti-PD-1antibody (pembrolizumab) plus T-VEC combination led to an increased tumor infiltration of IFN-γ+ CD8+ T cells in patients with tumors with low level of immune cell infiltrates and negative IFN-γ signatures [8]. This evidence concerns the gene CD8A and neoplasm.